Skip to main content
SpringerLink
Log in

Breast cancer OncoGuia

  • Special Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Manchon Walsh P, Borràs JM (2009) Clinical practice guidelines for cancer care: what are they for?. Clin Transl Oncol 11:775–776

    Article  PubMed  Google Scholar 

  2. National Institute for Health and Clinical Excellence (2007) The guidelines manual. National Institute for Health and Clinical Excellence, London. April. Available at www.nice.org.uk

  3. Izquierdo A, Gispert R, Saladie F, Espinàs JA (2008) Análisis de la incidencia, la supervivencia y la mortalidad según las principales localizaciones tumorales, 1985–2019: cáncer de mama. Med Clin Monogr (Barc) 9:50–52

    Article  Google Scholar 

  4. Cleries R, Ribes J, Esteban L et al (2006) Time trends of breast cancer mortality in Spain during the period 1977–2001 and Bayesian approach for projections during 2002–2016. Ann Oncol 17:1783–1791

    Article  CAS  PubMed  Google Scholar 

  5. Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792

    Article  CAS  PubMed  Google Scholar 

  6. (1996) Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol 14:1730–1736

  7. Burke W, Daly M, Garber J et al (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277:997–1003

    Article  CAS  PubMed  Google Scholar 

  8. Haagensen CD, Bodian C, Haagensen DE (1981) Breast carcinoma: risk and detection. Saunders, Philadelphia, PA

    Google Scholar 

  9. Morris KT, Pommier RF, Morris A et al (2001) Usefulness of the triple test score for palpable breast masses. Arch Surg 136:1008–1012; discussion 1012–1013

    Article  CAS  PubMed  Google Scholar 

  10. Scottish Intercollegiate Guidelines Network (2005) Management of breast cancer in women. Scottish Intercollegiate Guidelines Network

  11. Cady B, Steele GD Jr, Morrow M et al (1998) Evaluation of common breast problems: guidance for primary care providers. CA Cancer J Clin 48:49–63

    Article  CAS  PubMed  Google Scholar 

  12. Aisenberg AC, Finkelstein DM, Doppke KP et al (1997) High risk of breast carcinoma after irradiation of young women with Hodgkin’s disease. Cancer 79:1203–1210

    Article  CAS  PubMed  Google Scholar 

  13. Bhatia S, Robison LL, Oberlin O et al (1996) Breast cancer and other second neoplasms after childhood Hodgkin’s disease. N Engl J Med 334:745–751

    Article  CAS  PubMed  Google Scholar 

  14. Sickles EA (1988) Practical solutions to common mammographic problems: tailoring the examination. AJR Am J Roentgenol 151:31–39

    CAS  PubMed  Google Scholar 

  15. Sickles EA, Ominsky SH, Sollitto RA et al (1990) Medical audit of a rapid-throughput mammography screening practice: methodology and results of 27,114 examinations. Radiology 175:323–327

    CAS  PubMed  Google Scholar 

  16. Di Maggio C (2004) State of the art of current modalities for the diagnosis of breast lesions. Eur J Nucl Med Mol Imaging 31[Suppl 1]:S56–S69

    Article  PubMed  Google Scholar 

  17. D’Orsi CJ, Bassett LW, Berg WA et al (2005) Nonpalpable breast masses [online publication]. American College of Radiology (ACR), Reston, VA. Available at http://www.acr.org/Secondary-MainMenuCategories/quality_safety/app_criteria/pdf/ExpertPanelonWomensImagingBreastWork-Group/PalpableBreastMassesDoc3.aspx

    Google Scholar 

  18. American College of Radiology (ACR) (2003) ACR BI-RADS® mammography. In: ACR Breast Imaging Reporting and Data System, Breast Imaging Atlas, 4th edn. American College of Radiology, Reston, VA

    Google Scholar 

  19. Georgian-Smith D, Taylor KJ, Madjar H et al (2000) Sonography of palpable breast cancer. J Clin Ultrasound 28:211–216

    Article  CAS  PubMed  Google Scholar 

  20. Moy L, Slanetz PJ, Moore R et al (2002) Specificity of mammography and US in the evaluation of a palpable abnormality: retrospective review. Radiology 225:176–181

    Article  PubMed  Google Scholar 

  21. Parikh JR, Evans WP, Bassett L et al (2006) Expert Panel on Women’s Imaging: Breast. Palpable breast masses [online publication]. American College of Radiology (ACR), Reston VA

    Google Scholar 

  22. Bassett LW, Ysrael M, Gold RH, Ysrael C (1991) Usefulness of mammography and sonography in women less than 35 years of age. Radiology 180:831–835

    CAS  PubMed  Google Scholar 

  23. Ciatto S, Bravetti P, Bonardi R, Rosselli DT (1990) The role of mammography in women under 30. Radiol Med (Torino) 80:676–678

    CAS  Google Scholar 

  24. Slawson SH, Johnson BA (2001) Ductography: how to and what if? Radiographics 21:133–150

    CAS  PubMed  Google Scholar 

  25. Dinkel HP, Trusen A, Gassel AM et al (2000) Predictive value of galactographic patterns for benign and malignant neoplasms of the breast in patients with nipple discharge. Br J Radiol 73:706–714

    CAS  PubMed  Google Scholar 

  26. Pestalozzi B, Castiglione M (2008) Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19[Suppl 2]:ii7–10

    Article  PubMed  Google Scholar 

  27. Wallis M, Tardivon A, Helbich T, Schreer I (2007) Guidelines from the European Society of Breast Imaging for diagnostic interventional breast procedures. Eur Radiol 17:581–588

    Article  PubMed  Google Scholar 

  28. Rakha EA, Ellis IO (2007) An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens. J Clin Pathol 60:1300–1306

    Article  CAS  PubMed  Google Scholar 

  29. Chaiwun B, Thorner P (2007) Fine needle aspiration for evaluation of breast masses. Curr Opin Obstet Gynecol 19:48–55

    Article  PubMed  Google Scholar 

  30. Bartella L, Smith CS, Dershaw DD, Liberman L (2007) Imaging breast cancer. Radiol Clin North Am 45:45–67

    Article  PubMed  Google Scholar 

  31. Fisher B, Bauer M, Wickerham DL et al (1983) Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 52:1551–1557

    CAS  Google Scholar 

  32. Veronesi U, Paganelli G, Galimberti V et al (1997) Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymphnodes. Lancet 349:1864–1867

    Article  CAS  PubMed  Google Scholar 

  33. Gralow JR, Burstein HJ, Wood W et al (2008) Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 26:814–819

    Article  PubMed  Google Scholar 

  34. Alvarez S, Anorbe E, Alcorta P et al (2006) Role of sonography in the diagnosis of axillary lymph node metastases in breast cancer: a systematic review. AJR Am J Roentgenol 186:1342–1348

    Article  PubMed  Google Scholar 

  35. Davis JT, Brill YM, Simmons S et al (2006) Ultrasound-guided fine-needle aspiration of clinically negative lymph nodes versus sentinel node mapping in patients at high risk for axillary metastasis. Ann Surg Oncol 13:1545–1552

    Article  PubMed  Google Scholar 

  36. Moore A, Hester M, Nam MW et al (2008) Distinct lymph nodal sonographic characteristics in breast cancer patients at high risk for axillary metastases correlate with the final axillary stage. Br J Radiol 81:630–636

    Article  CAS  PubMed  Google Scholar 

  37. National Cancer Institute Committee on Breast Fine Needle Aspiration Biopsy (1997) The uniform approach to breast fine-needle aspiration biopsy. Breast J 3:149–168

    Article  Google Scholar 

  38. Bozzetti C, Nizzoli R, Guazzi A et al (2002) HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer. Ann Oncol 13:1398–1403

    Article  CAS  PubMed  Google Scholar 

  39. Sneige N (2004) Utility of cytologic specimens in the evaluation of prognostic and predictive factors of breast cancer: current issues and future directions. Diagn Cytopathol 30:158–165

    Article  PubMed  Google Scholar 

  40. Parker SH, Burbank F, Jackman RJ et al (1994) Percutaneous large-core breast biopsy: a multi-institutional study. Radiology 193:359–364

    CAS  PubMed  Google Scholar 

  41. Bassett L, Winchester DP, Caplan RB et al (1997) Stereotactic core-needle biopsy of the breast: a report of the Joint Task Force of the American College of Radiology, American College of Surgeons, and College of American Pathologists. CA Cancer J Clin 47:171–190

    Article  CAS  PubMed  Google Scholar 

  42. Bast RC Jr, Ravdin P, Hayes DF et al (2001) 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865–1878

    PubMed  Google Scholar 

  43. Cooke T, Reeves J, Lanigan A, Stanton P (2001) HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol 12[Suppl 1]:S23–S28

    Article  PubMed  Google Scholar 

  44. Eppenberger-Castori S, Kueng W, Benz C et al (2001) Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. J Clin Oncol 19:645–656

    CAS  PubMed  Google Scholar 

  45. Field AS, Chamberlain NL, Tran D, Morey AL (2001) Suggestions for HER-2/neu testing in breast carcinoma, based on a comparison of immunohistochemistry and fluorescence in situ hybridisation. Pathology 33:278–282

    Article  CAS  PubMed  Google Scholar 

  46. Ellis IO, Humphreys S, Michell M et al (2004) Best Practice No 179. Guidelines for breast needle core biopsy handling and reporting in breast screening assessment. J Clin Pathol 57:897–902

    Article  CAS  PubMed  Google Scholar 

  47. NHS Non-operative Diagnosis Subgroup of the National Coordinating Group for Breast Screening Pathology (2001) Core biopsy reporting guidelines. In: Guidelines for non-operative diagnostic procedures and reporting in breast cancer screening. NHSBSP Publication No. 50. NHS Cancer Screening Programmes, Sheffield, pp 32–45

    Google Scholar 

  48. Berg WA, Gutierrez L, NessAiver MS et al (2004) Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology 233:830–849

    Article  PubMed  Google Scholar 

  49. Heusinger K, Lohberg C, Lux MP et al (2005) Assessment of breast cancer tumor size depends on method, histopathology and tumor size itself. Breast Cancer Res Treat 94:17–23

    Article  CAS  PubMed  Google Scholar 

  50. Dummin LJ, Cox M, Plant L (2007) Prediction of breast tumor size by mammography and sonography: a breast screen experience. Breast 16:38–46

    Article  CAS  PubMed  Google Scholar 

  51. Bedrosian I, Mick R, Orel SG et al (2003) Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer 98:468–473

    Article  PubMed  Google Scholar 

  52. Van Goethem M, Schelfout K, Dijckmans L et al (2004) MR mammography in the pre-operative staging of breast cancer in patients with dense breast tissue: comparison with mammography and ultrasound. Eur Radiol 14:809–816

    Article  PubMed  Google Scholar 

  53. Bilimoria KY, Cambic A, Hansen NM, Bethke KP (2007) Evaluating the impact of preoperative breast magnetic resonance imaging on the surgical management of newly diagnosed breast cancers. Arch Surg 142:441–445

    Article  PubMed  Google Scholar 

  54. Ikeda O, Nishimura R, Miyayama H et al (2004) Magnetic resonance evaluation of the presence of an extensive intraductal component in breast cancer. Acta Radiol 45:721–725

    Article  CAS  PubMed  Google Scholar 

  55. Hata T, Takahashi H, Watanabe K et al (2004) Magnetic resonance imaging for preoperative evaluation of breast cancer: a comparative study with mammography and ultrasonography. J Am Coll Surg 198:190–197

    Article  PubMed  Google Scholar 

  56. Lee SG, Orel SG, Woo IJ et al (2003) MR imaging screening of the contralateral breast in patients with newly diagnosed breast cancer: preliminary results. Radiology 226:773–778

    Article  PubMed  Google Scholar 

  57. Slanetz PJ, Edmister WB, Yeh ED et al (2002) Occult contralateral breast carcinoma incidentally detected by breast magnetic resonance imaging. Breast J 8:145–148

    Article  PubMed  Google Scholar 

  58. Lehman CD, Gatsonis C, Kuhl CK et al (2007) MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 356:1295–1303

    Article  CAS  PubMed  Google Scholar 

  59. Mann RM, Kuhl CK, Kinkel K, Boetes C (2008) Breast MRI: guidelines from the European Society of Breast Imaging. Eur Radiol 18:1307–1318

    Article  CAS  PubMed  Google Scholar 

  60. (2008) Breast cancer. In: NCCN Practice Guidelines in Oncology, v.2.2008. National Comprehensive Cancer Network

  61. Liberman L, Morris EA, Dershaw DD et al (2003) MR imaging of the ipsilateral breast in women with percutaneously proven breast cancer. AJR Am J Roentgenol 180:901–910

    PubMed  Google Scholar 

  62. Kuhl C, Kuhn W, Braun M, Schild H (2007) Pre-operative staging of breast cancer with breast MRI: one step forward, two steps back? Breast 16[Suppl 2]:S34–S44

    Article  PubMed  Google Scholar 

  63. Swayampakula AK, Dillis C, Abraham J (2008) Role of MRI in screening, diagnosis and management of breast cancer. Exp Rev Anticancer Ther 8:811–817

    Article  Google Scholar 

  64. Orel S (2008) Who should have breast magnetic resonance imaging evaluation? J Clin Oncol 26:703–711

    Article  PubMed  Google Scholar 

  65. Fédération Nationale des centres de lutte contre le cancer (2007) Recommandations pour la pratique clinique: Saint Paul de Vence 2007 “cancer du sein”. France

  66. Kneeshaw PJ, Turnbull LW, Smith A, Drew PJ (2003) Dynamic contrast enhanced magnetic resonance imaging aids the surgical management of invasive lobular breast cancer. Eur J Surg Oncol 29:32–37

    Article  CAS  PubMed  Google Scholar 

  67. Greene FL, Page DL, Fleming ID et al (2002) AJCC Cancer Staging Manual, 6th edn. Springer Verlag, New York, NY

    Google Scholar 

  68. Singletary SE, Connolly JL (2006) Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin 56:37–47

    Article  PubMed  Google Scholar 

  69. Fisher B (1999) Highlights from recent National Surgical Adjuvant Breast and Bowel Project studies in the treatment and prevention of breast cancer. CA Cancer J Clin 49:159–177

    Article  CAS  PubMed  Google Scholar 

  70. Julien JP, Bijker N, Fentiman IS et al (2000) Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 355:528–533

    Article  CAS  PubMed  Google Scholar 

  71. Rastelli F, Crispino S (2008) Factors predictive of response to hormone therapy in breast cancer. Tumori 94:370–383

    PubMed  Google Scholar 

  72. Arriagada R, Le MG, Rochard F, Contesso G (1996) Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin Oncol 14:1558–1564

    CAS  PubMed  Google Scholar 

  73. Fisher B, Anderson S, Redmond CK et al (1995) Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 333:1456–1461

    Article  CAS  PubMed  Google Scholar 

  74. Silverstein MJ, Lagios MD, Groshen S et al (1999) The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 340:1455–1461

    Article  CAS  PubMed  Google Scholar 

  75. Veronesi U, Salvadori B, Luini A et al (1995) Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomised trials on 1,973 patients. Eur J Cancer 31A:1574–1579

    Article  CAS  PubMed  Google Scholar 

  76. Yang SH, Yang KH, Li YP et al (2008) Breast conservation therapy for stage I or stage II breast cancer: a meta-analysis of randomized controlled trials. Ann Oncol 19:1039–1044

    Article  CAS  PubMed  Google Scholar 

  77. Abner AL, Recht A, Vicini FA et al (1991) Cosmetic results after surgery, chemotherapy, and radiation therapy for early breast cancer. Int J Radiat Oncol Biol Phys 21:331–338

    CAS  PubMed  Google Scholar 

  78. Markiewicz DA, Schultz DJ, Haas JA et al (1996) The effects of sequence and type of chemotherapy and radiation therapy on cosmesis and complications after breast conservation therapy. Int J Radiat Oncol Biol Phys 35:661–668

    CAS  PubMed  Google Scholar 

  79. Granzow JW, Levine JL, Chiu ES, Allen RJ (2006) Breast reconstruction using perforator flaps. J Surg Oncol 94:441–454

    Article  PubMed  Google Scholar 

  80. Pinero A, Gimenez J, Merck B, Vazquez C (2007) [Consensus meeting on selective biopsy of the sentinel node in breast cancer. Spanish Society of Senology and Breast Disease]. Rev Esp Med Nucl 26:176–180

    Article  CAS  PubMed  Google Scholar 

  81. Lyman GH, Giuliano AE, Somerfield MR et al (2005) American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23:7703–7720

    Article  PubMed  Google Scholar 

  82. Veronesi U, Paganelli G, Viale G et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349:546–553

    Article  PubMed  Google Scholar 

  83. Bass SS, Lyman GH, McCann CR et al (1999) Lymphatic mapping and sentinel lymph node biopsy. Breast J 5:288–295

    Article  PubMed  Google Scholar 

  84. Bedrosian I, Reynolds C, Mick R et al (2000) Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer 88:2540–2545

    Article  CAS  PubMed  Google Scholar 

  85. Canavese G, Gipponi M, Catturich A et al (2000) Pattern of lymphatic drainage to the sentinel lymph node in breast cancer patients. J Surg Oncol 74:69–74

    Article  CAS  PubMed  Google Scholar 

  86. Teng S, Dupont E, McCann C et al (2000) Do cytokeratin-positive-only sentinel lymph nodes warrant complete axillary lymph node dissection in patients with invasive breast cancer? Am Surg 66:574–578

    CAS  PubMed  Google Scholar 

  87. Cody HS III, Fey J, Akhurst T et al (2001) Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures. Ann Surg Oncol 8:13–19

    Article  PubMed  Google Scholar 

  88. Cox CE (2001) Lymphatic mapping in breast cancer: combination technique. Ann Surg Oncol 8[9 Suppl]:67S–70S

    CAS  PubMed  Google Scholar 

  89. Cox CE, Nguyen K, Gray RJ et al (2001) Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg 67:513–519

    CAS  PubMed  Google Scholar 

  90. Cserni G (2001) The potential value of intraoperative imprint cytology of axillary sentinel lymph nodes in breast cancer patients. Am Surg 67:86–91

    CAS  PubMed  Google Scholar 

  91. de Cicco C, Cremonesi M, Luini A et al (1998) Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer. J Nucl Med 39:2080–2084

    PubMed  Google Scholar 

  92. Kamath VJ, Giuliano R, Dauway EL et al (2001) Characteristics of the sentinel lymph node in breast cancer predict further involvement of high-er-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection. Arch Surg 136:688–692

    Article  CAS  PubMed  Google Scholar 

  93. Eary JF, Mankoff DA, Dunnwald LK et al (1999) Sentinel lymph node mapping for breast cancer: analysis in a diverse patient group. Radiology 213:526–529

    CAS  PubMed  Google Scholar 

  94. Giuliano AE, Haigh PI, Brennan MB et al (2000) Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 18:2553–2559

    CAS  PubMed  Google Scholar 

  95. Haigh PI, Hansen NM, Giuliano AE et al (2000) Factors affecting sentinel node localization during preoperative breast lymphoscintigraphy. J Nucl Med 41:1682–1688

    CAS  PubMed  Google Scholar 

  96. McMasters KM, Tuttle TM, Carlson DJ et al (2000) Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 18:2560–2566

    CAS  PubMed  Google Scholar 

  97. Dupont E, Cox C, Shivers S et al (2001) Learning curves and breast cancer lymphatic mapping: institutional volume index. J Surg Res 97:92–96

    Article  CAS  PubMed  Google Scholar 

  98. Cserni G (1999) Metastases in axillary sentinel lymph nodes in breast cancer as detected by intensive histopathological work up. J Clin Pathol 52:922–924

    Article  CAS  PubMed  Google Scholar 

  99. Cox CE, Bass SS, Boulware D et al (1999) Implementation of new surgical technology: outcome measures for lymphatic mapping of breast carcinoma. Ann Surg Oncol 6:553–561

    Article  CAS  PubMed  Google Scholar 

  100. Krag D, Weaver D, Ashikaga T et al (1998) The sentinel node in breast cancer: a multicenter validation study. N Engl J Med 339:941–946

    Article  CAS  PubMed  Google Scholar 

  101. Morrow M, Rademaker AW, Bethke KP et al (1999) Learning sentinel node biopsy: results of a prospective randomized trial of two techniques. Surgery 126:714–720

    CAS  PubMed  Google Scholar 

  102. Schrenk P, Rieger R, Shamiyeh A, Wayand W (2000) Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 88:608–614

    Article  CAS  PubMed  Google Scholar 

  103. Schwartz GF, Guiliano AE, Veronesi U (2002) Proceeding of the consensus conference of the role of sentinel lymph node biopsy in carcinoma or the breast April 19—22, 2001, Philadelphia, PA, USA. Breast J 8:124–138

    Article  PubMed  Google Scholar 

  104. Sociedad Española de Cirugía Oncológica (2002) Conferencia de consenso sobre el ganglio centinela en el cáncer de mama. Rev Senología y Patol Mam 15:92–94

    Google Scholar 

  105. (2001) Reunión Nacional Consenso sobre Ganglio Centinela y Cáncer de Mama. Asociación Española de Cirujanos, Sociedad Española de Medicina Nuclear y la Sociedad Española de Anatomia Patológica, celebrado en: Salamanca el 5 de Octubre de 2001 [on-line]. Available at http://www aecirujanos.es/formacion/ganglio.html. Accessed 9 November 2003

  106. Jansen L, Doting MH, Rutgers EJ et al (2000) Clinical relevance of sentinel lymph nodes outside the axilla in patients with breast cancer. Br J Surg 87:920–925

    Article  CAS  PubMed  Google Scholar 

  107. Johnson N, Soot L, Nelson J et al (2000) Sentinel node biopsy and internal mammary lymphatic mapping in breast cancer. Am J Surg 179:386–388

    Article  CAS  PubMed  Google Scholar 

  108. Nason KS, Anderson BO, Byrd DR et al (2000) Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 89:2187–2194

    Article  CAS  PubMed  Google Scholar 

  109. Rahusen FD, Pijpers R, Van Diest PJ et al (2000) The implementation of the sentinel node biopsy as a routine procedure for patients with breast cancer. Surgery 128:6–12

    Article  CAS  PubMed  Google Scholar 

  110. Eiermann W, Paepke S, Appfelstaedt J et al (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12:1527–1532

    Article  CAS  PubMed  Google Scholar 

  111. Fisher B, Dignam J, Wolmark N et al (1998) Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16:441–452

    CAS  PubMed  Google Scholar 

  112. Fisher B, Anderson S, Wickerham DL et al (1997) Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15:1858–1869

    CAS  PubMed  Google Scholar 

  113. Gazet JC, Markopoulos C, Ford HT et al (1988) Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer. Lancet 1:679–681

    Article  CAS  PubMed  Google Scholar 

  114. Mustacchi G, Milani S, Pluchinotta A et al (1994) Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: the G.R.E.T.A. Trial. Group for Research on Endocrine Therapy in the Elderly. Anticancer Res 14:2197–2200

    CAS  PubMed  Google Scholar 

  115. Robertson JF, Ellis IO, Elston CW, Blamey RW (1992) Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up. Eur J Cancer 28A:908–910

    Article  CAS  PubMed  Google Scholar 

  116. Eisen A, Trudeau M, Shelley W, Sinclair S, Breast Cancer Disease Site Group (2008) The role of aromatase inhibitors in adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: guideline recommendations. Cancer Care Ontario (CCO), Toronto

    Google Scholar 

  117. Trudeau M, Singh B, Clemons M, Shelley W (2004) The role of taxanes in neoadjuvant chemotherapy for women with non-metastatic breast cancer. Practice guideline report #1–20. Cancer Care Ontario (CCO), Toronto

    Google Scholar 

  118. Guarneri V, Frassoldati A, Piacentini F et al (2008) Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial). Clin Breast Cancer 8:192–194

    Article  CAS  PubMed  Google Scholar 

  119. Madarnas Y, Trudeau M, Franek JA et al (2008) Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review. Cancer Treat Rev 34:539–557

    Article  CAS  PubMed  Google Scholar 

  120. Favret AM, Carlson RW, Goffinet DR et al (2001) Locally advanced breast cancer: is surgery necessary? Breast J 7:131–137

    Article  CAS  PubMed  Google Scholar 

  121. Hortobagyi GN, Singletary SE, Strom E (2000) Treatment of locally advanced and inflammatory breast cancer. In: Harris JR, Lippman M, Morrow M, Osborne CK (eds) Diseases of the breast. Lippincott & Wilkins, Philadelphia, PA, pp 645–660

    Google Scholar 

  122. National Cancer Institute (2003) Common terminology criteria for adverse events v3.0 (CTCAE) [on-line]. Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD. Available at http://ctep.cancer.gov. Accessed 10 September 2003

    Google Scholar 

  123. (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 352:930–942

  124. French Adjuvant Study Group (2001) Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 19:602–611

    Google Scholar 

  125. Fisher B, Brown AM, Dimitrov NV et al (1990) Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483–1496

    CAS  PubMed  Google Scholar 

  126. De Laurentiis M, Cancello G, D’Agostino D et al (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26:44–53

    Article  PubMed  CAS  Google Scholar 

  127. Martin M, Villar A, Sole-Calvo A et al (2003) Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann Oncol 14:833–842

    Article  CAS  PubMed  Google Scholar 

  128. Buzdar AU, Kau SW, Smith TL, Hortobagyi GN (1989) Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol 12:123–128

    CAS  PubMed  Google Scholar 

  129. Assikis V, Buzdar A, Yang Y et al (2003) A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up. Cancer 97:2716–2723

    Article  CAS  PubMed  Google Scholar 

  130. Bull JM, Tormey DC, Li SH et al (1978) A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 41:1649–1657

    Article  CAS  PubMed  Google Scholar 

  131. Levine MN, Bramwell VH, Pritchard KI et al (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:2651–2658

    CAS  PubMed  Google Scholar 

  132. Henderson IC, Berry DA, Demetri GD et al (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976–983

    Article  CAS  PubMed  Google Scholar 

  133. Mamounas EP, Bryant J, Lembersky B et al (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23:3686–3696

    Article  CAS  PubMed  Google Scholar 

  134. Piccart MJ, Di Leo A, Beauduin M et al (2001) Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 19:3103–3110

    CAS  PubMed  Google Scholar 

  135. Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302–2313

    Article  CAS  PubMed  Google Scholar 

  136. Bonadonna G, Zambetti M, Valagussa P (1995) Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 273:542–547

    Article  CAS  PubMed  Google Scholar 

  137. Poole CJ, Earl HM, Hiller L et al (2006) Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 355:1851–1862

    Article  CAS  PubMed  Google Scholar 

  138. Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431–1439

    Article  CAS  PubMed  Google Scholar 

  139. Roche H, Fumoleau P, Spielmann M et al (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 24:5664–5671

    Article  CAS  PubMed  Google Scholar 

  140. Jones SE, Savin MA, Holmes FA et al (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381–5387

    Article  CAS  PubMed  Google Scholar 

  141. Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684

    Article  CAS  PubMed  Google Scholar 

  142. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809–820

    Article  CAS  PubMed  Google Scholar 

  143. Slamon D, Eiermann W, Robert N et al (2005) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HE2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 24[Suppl 1]:S5

    Google Scholar 

  144. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672

    Article  CAS  PubMed  Google Scholar 

  145. Bartelink H, Rubens RD, van der SE, Sylvester R (1997) Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer Randomized Phase III Trial. J Clin Oncol 15:207–215

    CAS  PubMed  Google Scholar 

  146. Boccardo F, Rubagotti A, Amoroso D et al (2000) Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 18:2718–2727

    CAS  PubMed  Google Scholar 

  147. Fisher B, Dignam J, Wolmark N et al (1999) Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353:1993–2000

    Article  CAS  PubMed  Google Scholar 

  148. Fisher B, Anderson S, Tan-Chiu E et al (2001) Tamoxifen and chemotherapy for axillary nodenegative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 19:931–942

    CAS  PubMed  Google Scholar 

  149. Klijn JG, Blamey RW, Boccardo F et al (2001) Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19:343–353

    CAS  PubMed  Google Scholar 

  150. Early Breast Cancer Trialists’ Collaborative Group (1995) Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl J Med 333:1444–1455

    Article  Google Scholar 

  151. Baum M, Budzar AU, Cuzick J et al (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–2139

    Article  CAS  PubMed  Google Scholar 

  152. Bonneterre J, Thurlimann B, Robertson JF et al (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18:3748–3757

    CAS  PubMed  Google Scholar 

  153. Buzdar AU, Jonat W, Howell A et al (1998) Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 83:1142–1152

    Article  CAS  PubMed  Google Scholar 

  154. Overgaard M, Jensen MB, Overgaard J et al (1999) Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 353:1641–1648

    Article  CAS  PubMed  Google Scholar 

  155. Overgaard M, Hansen PS, Overgaard J et al (1997) Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 337:949–955

    Article  CAS  PubMed  Google Scholar 

  156. Ragaz J, Jackson SM, Le N et al (1997) Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337:956–962

    Article  CAS  PubMed  Google Scholar 

  157. Recht A, Edge SB, Solin LJ et al (2001) Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1539–1569

    CAS  PubMed  Google Scholar 

  158. Vujovic O, Perera F, Dar AR et al (1998) Does delay in breast irradiation following conservative breast surgery in node-negative breast cancer patients have an impact on risk of recurrence? Int J Radiat Oncol Biol Phys 40:869–874

    Article  CAS  PubMed  Google Scholar 

  159. Buchholz TA, Austin-Seymour MM, Moe RE et al (1993) Effect of delay in radiation in the combined modality treatment of breast cancer. Int J Radiat Oncol Biol Phys 26:23–35

    CAS  PubMed  Google Scholar 

  160. Nixon AJ, Recht A, Neuberg D et al (1994) The relation between the surgery-radiotherapy interval and treatment outcome in patients treated with breast-conserving surgery and radiation therapy without systemic therapy. Int J Radiat Oncol Biol Phys 30:17–21

    CAS  PubMed  Google Scholar 

  161. Ruo Redda MG, Verna R, Guarneri A, Sannazzari GL (2002) Timing of radiotherapy in breast cancer conserving treatment. Cancer Treat Rev 28:5–10

    Article  PubMed  Google Scholar 

  162. Fiets WE, van Helvoirt RP, Nortier JW et al (2003) Acute toxicity of concurrent adjuvant radiotherapy and chemotherapy (CMF or AC) in breast cancer patients. a prospective, comparative, nonrandomised study. Eur J Cancer 39:1081–1088

    Article  CAS  PubMed  Google Scholar 

  163. Tubiana-Mathieu N, Lejeune C, Bonnier P et al (2001) Chemotherapy and concomitant irradiation in inflammatory breast cancer. Anticancer Res 21:3061–3067

    CAS  PubMed  Google Scholar 

  164. Arcangeli G, Pinnaro P, Rambone R et al (2006) A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer. Int J Radiat Oncol Biol Phys 64:161–167

    PubMed  Google Scholar 

  165. Dubey A, Recht A, Come SE et al (1999) Concurrent CMF and radiation therapy for early stage breast cancer: results of a pilot study. Int J Radiat Oncol Biol Phys 45:877–884

    CAS  PubMed  Google Scholar 

  166. Montemurro F, Gatti M, Redana S et al (2006) Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer. J Chemother 18:90–97

    CAS  PubMed  Google Scholar 

  167. Kuerer HM, Gwyn K, Ames FC, Theriault RL (2002) Conservative surgery and chemotherapy for breast carcinoma during pregnancy. Surgery 131:108–110

    Article  PubMed  Google Scholar 

  168. Bijker N, Meijnen P, Peterse JL et al (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853: a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24:3381–3387

    Article  PubMed  Google Scholar 

  169. Antonini N, Jones H, Horiot JC et al (2007) Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. Radiother Oncol 82:265–271

    Article  PubMed  Google Scholar 

  170. Omlin A, Amichetti M, Azria D et al (2006) Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol 7:652–656

    Article  PubMed  Google Scholar 

  171. Algara M, Sanz X, Foro P et al (2007) Risk factors of local relapse in breast cancer: the importante of age. Clin Transl Oncol 9:110–116

    Article  Google Scholar 

  172. Singletary SE (1994) Lobular carcinoma in situ pf the breast: a 31-year experience at the University of Texas M.D. Anderson Cancer Center. Breast Dis 8:157–163

    Google Scholar 

  173. Brito RA, Valero V, Buzdar AU et al (2001) Longterm results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 19:628–633

    CAS  PubMed  Google Scholar 

  174. Truong PT, Woodward WA, Thames HD et al (2007) The ratio of positive to excised nodes identifies high-risk subsets and reduces inter-institutional differences in locoregional recurrence risk estimates in breast cancer patients with 1–3 positive nodes: an analysis of prospective data from British Columbia and the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys 68:59–65

    PubMed  Google Scholar 

  175. Overgaard M, Nielsen HM, Overgaard J (2007) Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 82:247–253

    Article  PubMed  Google Scholar 

  176. Algara M, Foro P, Reig A et al (1999) Utilidad del hipofraccionamiento. Resultados preliminares. Oncología 22:35–40

    Article  Google Scholar 

  177. Ellis M, Hayed D, Lippman M (2004) Treatment of metastatic disease. In: Harris JE, Lipman ME, Morrow M, Osborne KE (eds) Diseases of the breast, 3rd edn. Lippincott Williams and Wilkins, Philadelphia, pp 1101–1134

    Google Scholar 

  178. Mouridsen H, Gershanovich M, Sun Y et al (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596–2606

    CAS  PubMed  Google Scholar 

  179. Paridaens R, Dirix L, Lohrisch C et al (2003) Mature results of a randomized phase II multi-center study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 14:1391–1398

    Article  CAS  PubMed  Google Scholar 

  180. Osborne CK, Pippen J, Jones SE et al (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20:3386–3395

    Article  CAS  PubMed  Google Scholar 

  181. Howell A, Robertson JF, Quaresma AJ et al (2002) Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20:3396–3403

    Article  CAS  PubMed  Google Scholar 

  182. Fossati R, Confalonieri C, Torri V et al (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16:3439–3460

    CAS  PubMed  Google Scholar 

  183. Sledge GW, Neuberg D, Bernardo P et al (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21:588–592

    Article  PubMed  Google Scholar 

  184. Alba E, Martin M, Ramos M et al (2004) Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 22:2587–2593

    Article  CAS  PubMed  Google Scholar 

  185. Albain KS, Nag S, Calderillo-Ruiz G et al (2004) Global phase III study of gemcitabine plus paclitaxel vs. paclitaxel as frontline therapy for metastatic breast cancer: first report of overall survival. J Clin Oncol 22:5S

    Google Scholar 

  186. Gennari A, Amadori D, De Lena M et al (2006) Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol 24:3912–3918

    Article  CAS  PubMed  Google Scholar 

  187. Alba E, Ruiz-Borrego M, Martin M et al (2007) Prolongation of TTP by maintenance therapy with PLD in a multicenter phase III randomized trial following standard chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. J Clin Oncol 25[18S]:1007

    Google Scholar 

  188. O’shaughnessy J, Miles D, Vukelja S et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812–2823

    Article  PubMed  CAS  Google Scholar 

  189. Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726

    Article  CAS  PubMed  Google Scholar 

  190. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

    Article  CAS  PubMed  Google Scholar 

  191. Marty M, Cognetti F, Maraninchi D et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23:4265–4274

    Article  CAS  PubMed  Google Scholar 

  192. Burstein HJ, Harris LN, Marcom PK et al (2003) Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21:2889–2895

    Article  CAS  PubMed  Google Scholar 

  193. Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743

    Article  CAS  PubMed  Google Scholar 

  194. Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676

    Article  CAS  PubMed  Google Scholar 

  195. Miles D, Chan A, Romieu G (2008) Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer: AVADO. J Clin Oncol 26: abs LBA1011

  196. Patchell RA, Tibbs PA, Walsh JW et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494–500

    Article  CAS  PubMed  Google Scholar 

  197. Rosselli Del Turco M, Palli D, Cariddi A et al (1994) Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA 271:1593–1597

    Article  CAS  PubMed  Google Scholar 

  198. Smith TJ, Davidson NE, Schapira DV et al (1999) American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 17:1080–1082

    CAS  PubMed  Google Scholar 

  199. (1994) Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. JAMA 271:1587–1592

  200. Kataja V, Castiglione M, ESMO Guidelines Working Group (2009) Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol Suppl 4:10–14

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Catalan Cancer Strategy, Department of Health, Avenida Gran Vía, s/n - km, 2,7, ES-08907, Barcelona, Spain

    Paula Manchon

Authors
  1. Paula Manchon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Josep M. Borràs
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tàrsila Ferro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Josep Alfons Espinàs
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the Breast Cancer OncoGuia Group

Corresponding author

Correspondence to Paula Manchon.

Additional information

Breast cancer experts are listed at the end of the article

Note

The OncoGuies, evidence-based guidelines in cancer in Catalonia, are the key element used by the Catalan Cancer Strategy in order to promote equity of access to therapy and quality of cancer care [1].

The instruments used here to grade the scientific evidence were the Scottish Intercollegiate Guidelines Network (SIGN) scale to evaluate therapeutic intervention studies (1++;4) and the Centre for Evidence-Based Medicine (CEBM-OXFORD) scale to evaluate diagnostic intervention studies (Ia-IV) [2].

The consensus categories (Standard [S] and Consensus option [CO] and Option [O]) were devised bearing in mind currently valid recommendations of the National Cancer Institute, the National Comprehensive Cancer Network, the Scottish Intercollegiate Guidelines Network, the Institute for Clinical Systems Improvement and the Fédération Nationale des Centres de Lutte Contre le Cancer.

A standard recommendation is considered when the entire working group agrees on recommending a particular intervention within the specific context of the algorithm.

A recommendation is considered as a consensus option when the majority (at least 90%) of the working group agrees on recommending a particular intervention within the specific context of the algorithm. Finally a recommendation is considered as an option when there are major discrepancies as to whether a particular intervention should be recommended or not and no majority consensus was reached by the working group.

Occasionally the working groups were unable to identify evidence supporting important clinical aspects that are considered to be good practice point (GPP).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Manchon, P., Borràs, J.M., Ferro, T. et al. Breast cancer OncoGuia. Clin Transl Oncol 12, 113–137 (2010). https://doi.org/10.1007/S12094-010-0477-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/S12094-010-0477-9

Keywords

Search

Navigation